Naixin Liang Selected Research

Naixin Liang Research Topics

Disease

26	Neoplasms (Cancer) 02/2024 - 07/2015
23	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 07/2015
16	Lung Neoplasms (Lung Cancer) 04/2024 - 12/2015
6	Adenocarcinoma of Lung 07/2022 - 09/2017
5	Neoplasm Metastasis (Metastasis) 01/2020 - 09/2017
4	Adenocarcinoma 11/2023 - 01/2020
3	Carcinogenesis 01/2021 - 02/2017
2	Esophageal Neoplasms (Esophageal Cancer) 01/2021 - 01/2018
2	Melanoma (Melanoma, Malignant) 01/2021 - 01/2018
2	Circulating Neoplastic Cells 08/2020 - 05/2018
1	Arthritis (Polyarthritis) 03/2024
1	Inflammation (Inflammations) 03/2024
1	Port-Wine Stain (Nevus Flammeus) 11/2022
1	Vascular Malformations 11/2022
1	Microsatellite Instability 01/2022
1	Oliguria 01/2021
1	Thymoma (Thymic Carcinoma) 01/2021
1	Tumor Lysis Syndrome 01/2021
1	Fever (Fevers) 01/2021
1	Disease Progression 01/2021
1	Connective Tissue Diseases (Connective Tissue Disease) 11/2020
1	Pathologic Complete Response 11/2020
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/2017
1	Postoperative Pain 09/2017
1	Pain (Aches) 09/2017
1	Chronic Pain 09/2017
1	Lymphatic Metastasis 12/2016
1	Primitive Neuroectodermal Tumors (PNET) 02/2013

Drug/Important Bio-Agent (IBA)

6	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 01/2021
5	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2018
5	ErbB Receptors (EGF Receptor)IBA 10/2022 - 03/2017
4	IntegrinsIBA 01/2023 - 12/2015
4	Tyrosine Kinase InhibitorsIBA 10/2022 - 03/2017
4	Biomarkers (Surrogate Marker)IBA 02/2022 - 01/2018
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2024 - 01/2021
3	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2020
3	CrizotinibIBA 11/2023 - 01/2019
3	RNA (Ribonucleic Acid)IBA 04/2022 - 10/2020
3	Long Noncoding RNAIBA 12/2021 - 02/2017
2	Cell-Free Nucleic AcidsIBA 11/2022 - 07/2022
2	B7-H1 AntigenIBA 09/2022 - 01/2022
2	MicroRNAs (MicroRNA)IBA 02/2022 - 10/2018
2	AntigensIBA 01/2021 - 01/2018
2	Peptides (Polypeptides)IBA 08/2020 - 12/2016
2	Carcinoembryonic AntigenIBA 01/2020 - 01/2020
2	Messenger RNA (mRNA)IBA 01/2019 - 07/2015
1	Adenosine Triphosphate (ATP)IBA 09/2023
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 11/2022
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 09/2022
1	Angiogenesis InhibitorsIBA 08/2022
1	CXC ChemokinesIBA 02/2022
1	Gefitinib (Iressa)FDA Link 12/2021
1	ceritinibIBA 01/2021
1	brigatinibIBA 01/2021
1	Anaplastic Lymphoma KinaseIBA 01/2021
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 11/2020
1	Circulating Tumor DNAIBA 04/2020
1	Competitive Endogenous RNAIBA 01/2020
1	Sincalide FDA Link 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2019
1	Factor VIII (Coagulation Factor VIII)IBA 01/2019
1	Kruppel-Like Transcription Factors (Kruppel-Like Factors)IBA 01/2019
1	ERRalpha Estrogen-Related ReceptorIBA 07/2018
1	Interleukin-6 (Interleukin 6)IBA 07/2018
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 05/2018
1	ChitosanIBA 12/2017
1	Folic Acid (Vitamin M)FDA LinkGeneric 12/2017
1	Temozolomide (Temodar)FDA LinkGeneric 12/2017
1	Nicotinamide PhosphoribosyltransferaseIBA 10/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2017
1	SolutionsIBA 03/2017
1	aspartic acid glycine arginineIBA 12/2016
1	Technetium (Technetium 99m)IBA 12/2016
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 12/2016
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2016
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 12/2015
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 07/2015
1	Cisplatin (Platino)FDA LinkGeneric 07/2015

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 02/2024 - 02/2013
4	Immunotherapy 01/2022 - 11/2020
3	Precision Medicine 02/2024 - 04/2020
3	Therapeutics 10/2022 - 01/2020
1	Aftercare (After-Treatment) 01/2021
1	Adjuvant Chemotherapy 04/2020
1	Preoperative Exercise 01/2020
1	Lymph Node Excision (Lymph Node Dissection) 01/2020
1	Thoracotomy 09/2017
1	Pain Management 09/2017
1	Radiotherapy 02/2013